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Background: Tofacitinib is a partially selective Janus kinase inhibitor 
that was approved for the treatment of refractory moderate to severe 
ulcerative colitis (UC) in 2018. We report the real-world clinical ef-
fectiveness and adverse effects of tofacitinib in UC.
Methods: We conducted a retrospective observational cohort 
study of tofacitinib-treated patients with UC between October 
2018 to October 2019 from 4 UK centres. Disease activity was 
assessed using the Simple Clinical Colitis Activity Index (SCCAI) 
or Partial Mayo Score (PMS) depending on the study site. 
Response and remission were defined at week 8 and 26 as a re-
duction in SCCAI or PMS of ≥3, and SCCAI <3 or PMS <2, re-
spectively. Corticosteroid-free remission was defined as remission 
with no corticosteroid use at the time of assessment irrespective 
of baseline corticosteroid status.
Results: We included 140 patients (65% M; median age 37y [range 
16–81]) with a median disease duration of 5.5y (IQR 2.2–11.8). 
Forty-six per cent (65/140) were receiving corticosteroids at baseline 
and 83% (116/140) had previously received at least one biologic 
(62 anti-TNF, 4 vedolizumab, 50 both). Median (IQR) serum CRP 
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Response and remission rates were 73% (81/111) and 56% (62/111) 
respectively at week 8 (median ΔSCCAI of −3 [IQR -6 to -1], median 
ΔPMS −4 [−6 to −1]) and 48% (39/82) and 39% (32/82) respectively 
at week 26 (median ΔSCCAI −3 [IQR −7 to –1], median ΔPMS −4 
[−6 to –1]). Steroid-free remission was seen in 47% (52/111) and 
37% (30/82) patients at week 8 and 26. Patients with response or re-
mission had a significantly lower CRP (p = 0.02) but not calprotectin 
(p = 0.38) levels at baseline. Response and remission rates were no 
different stratified by prior biologic use (p = 0.56). Treatment was 
discontinued after a median of 3 months (IQR 2–4) in 43 patients: 
32 with primary non-response, 9 loss of response and in 1 each be-
cause of an adverse drug reaction (headache) and patient choice. 7/17 
patients had a clinical response to dose re-escalation following a loss 
of response on dose reduction. The median time to dose de-escalation 
was 67 (IQR 25–240) days. Seven patients were hospitalised and 
5 underwent colectomy. Six serious infections were noted includ-
ing 2 herpes zoster infections but there were no venous thrombo-
embolic events. Median total cholesterol, low-density lipoprotein and 
high-density lipoprotein increased from 4.4 mmol/l (IQR 3.7–5.2), 
2.47 (1.9–2.9) and 1.5 (1.1–1.9) to 4.8 mmol/l (4.1–6.0), 2.8 (2.13.5) 
and 1.7 (1.4–1.9) respectively after 8 weeks of tofacitinib.
Conclusion: PF-06480605 exhibited an acceptable safety and tol-
erability profile and statistically significant EI in participants with 
moderate to severe UC. These results warrant further evaluation in 
subsequent studies.
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Background: The pathogenesis of IBD has previously mainly been 
associated with a dysregulation of CD4 T-cell responses, and 
active disease is linked to induction of pathogenic IL-17 produc-
ing T helper cells. Importantly, CD8 T cells can also produce IL-17 
and demonstrate a significant increase in active IBD. However, it 
remains unclear whether this is due to conventional or unconven-
tional T-cell responses and whether these CD8 responses could play 
a role as novel biomarkers or therapeutic targets of active IBD.
Methods: We isolated lymphocytes from the peripheral blood and 
intestinal tissue of IBD patients (n = 56) and performed a detailed 
analysis of CD8 T-cell phenotype and function using high-parametric 
flow cytometry and mass cytometry in combination with algorithm-
aided bioinformatic analysis.
Results: We observe a significant increase in IL-17 production by 
CD8 T cells in active IBD, primarily produced by conventional 
CD8 T cells. Unconventional T-cell subsets (e.g. MAIT cells, γδ T 
cells and NKT cells) represented only ~30% (peripheral blood) or 
~25% (intestinal tissue) of IL-17 producing CD8 T cells (Tc17). 
The mass cytometric analysis identified Tc17 cells as a distinct 
cell population within the intestinal CD8 T-cell compartment that 
can be further subdivided into 3 subsets which share expression 
of phenotypic markers such as CD6, CD39, CD69 and PD1 and a 
low expression of CD27. This novel signature was validated in a 
separate cohort of IBD patients. Moreover, at initial IBD diagnosis, 
the IL-17 signature is associated with flare-free survival in a retro-
spective cohort analysis based on published transcriptome data.
Conclusion: Our data indicate that conventional IL-17 producing CD8 
T cells are a very distinct cell population that is linked to IBD activity. 
The identification of a novel IL-17 CD8 signature may help guide treat-
ment decisions as a biomarker and for immunotherapeutic approaches.
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UniStar, a phase 1 study
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